Hair Restoration Approaches for Early Onset Male Androgenetic Alopecia

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

Breezula, a new topical hair loss treatment, is expected to be expensive, with an estimated cost of €300 per month, making it less accessible compared to cheaper alternatives like finasteride. Some users discuss the potential for cheaper generics from countries like China and India, while others debate the effectiveness and pricing strategy of Breezula compared to other treatments like minoxidil and RU58841.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

A user is concerned about facial puffiness potentially caused by minoxidil, but others suggest it might be due to aging, lighting, or water retention. The user has been using topical minoxidil for 8 months and recently started oral minoxidil, noticing changes in facial appearance.

A 31-year-old Australian had a successful hair transplant in Turkey for $10,000 AUD, using minoxidil and finasteride to combat hair loss. He now has a full head of hair, increased confidence, and continues using finasteride with occasional minoxidil.

The user regrets not starting finasteride at 1 mg daily from the beginning, as they feel their initial microdosing was ineffective. They are now on the standard dosage and hope to see improvements in hair loss over the next few months.